Aquestive Therapeutics, Inc.

WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster presentations will be featured at the 2026 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting, taking place November 12-16, 2026, in Phoenix, Arizona.

Aquestive Therapeutics, Inc. (NASDAQ: AQST - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders purchased 6,009 put options on the company. This is an increase of approximately 141% compared to the average daily volume of 2,494 put options. Analysts Set New Price Targets A number of analysts have

Aquestive Therapeutics, Inc. ( AQST ) Q3 2026 Earnings Call November 4, 2026 8:00 AM EST Company Participants Faith Pomeroy-Ward Daniel Barber - CEO, President & Director Ernie Toth - Senior VP & CFO Sherry Korczynski - Chief Commercial Officer Melina Cioffi - Senior Vice President of Regulatory Affairs Matthew Greenhawt - Chief Medical Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division D…

Aquestive Therapeutics NASDAQ: AQST said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administration approval.

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.14 per share a year ago.

Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approved Commercial preparations remain on track to support a potential U.S. launch of Anaphylm following FDA approval Ex-U.S. Anaphylm strategy progressing, with Health Canada submission expected in Q4 2026 and an EU filing planned for Q1 2027 Company to host investor call on November 4, 2026, …

Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.

WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report financial results for the third quarter ended September 30, 2026, and provide an update on recent developments in its business after market close on Tuesday, November 3, 2026.

Aquestive Therapeutics, Inc. (NASDAQ: AQST - Get Free Report) CEO Daniel Barber sold 25,000 shares of Aquestive Therapeutics stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $4.22, for a total transaction of $105,500.00. Following the completion of the sale, the chief executive officer owned 627,317

Aquestive Therapeutics received FDA acceptance for the Anaphylm NDA resubmission, targeting a March 16, 2027 PDUFA date. Resubmission addresses prior FDA concerns with improved human factors data, showing a significant reduction in packaging and administration errors. I upgrade AQST to Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030, despite competitive and reimbursement risks.

WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film for the treatment of Type I allergic reac…

SAN FRANCISCO, Oct. 7, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises Aquestive Therapeutics, Inc. (Nasdaq: AQST) investors that the firm is investigating potential legal claims arising from alleged false and misleading statements about the company's drug candidate Anaphylm. Current shareholders are encouraged to contact the firm here: https://www.classactionlawyers.com/aquestive.

Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, toda…

Squarepoint Ops LLC reduced its position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) by 71.8% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,422 shares of the company's stock after selling 179,060 shares during the period. Squarepoint Ops LLC owned about

Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026 FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innov…

BlackRock Inc. bought a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,069,373 shares of the company's stock, valued at approximately $33,569,000. BlackRock Inc. owned 6.43% of Aquestive Therapeutics as of its most recent

WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:

AWM Investment Company Inc. purchased a new position in Aquestive Therapeutics, Inc. (NASDAQ: AQST) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 475,400 shares of the company's stock, valued at approximately $1,978,000. AWM Investment Company Inc. owned

Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings Call Transcript

Aquestive Therapeutics NASDAQ: AQST said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Administration.